RRM2B

Across TCGA pan-cancer cohorts, RRM2B Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated RRM2B data layer compared with 18 for mass-spec protein and 4 for mass-spec protein.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher RRM2B Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated RRM2B expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

HNSC, LUAD, and SKCM are the cancer types where RRM2B Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	OS	Median	All	0.198	0.768	.001	33	view →
LUAD	OS	Median	All	0.223	0.788	.002	21	view →
SKCM	DFS	Median	All	0.016	0.758	<.001	15	view →
COAD	DFS	Median	All	0.245	0.690	.016	9	view →
UCEC	DFS	Median	All	1.000	0.637	.045	4	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

RRM2B–HNSC (OS)

Open the HNSC breakdown →